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Abstract
Background: Nurr1 is an orphan member of the nuclear receptor superfamily; these orphan
receptors are a group for which a ligand has yet to be identified. Nurr1 has been shown to regulate
the expression of a small number of genes as a monomeric, constitutively active receptor. These
Nurr1 regulated genes are primarily associated with dopamine cell maturation and survival.
However, previous reports have shown an increased expression of Nurr1 in the synovium of
patients with rheumatoid arthritis (RA) suggesting a pro-inflammatory role for Nurr1 in RA. In this
study we investigate the potential pro-inflammatory role of Nurr1 by monitoring Nurr1 dependent
gene expression in an immortalised synoviocyte cell line, K4IM.
Methods: We overexpressed the wild type and a dominant negative form of the orphan nuclear
receptor Nurr1, in a model synoviocyte cell line. Using the Affymetrix HG-U133 Genechips we
demonstrate the effects on the transcriptome by the receptor. Further evidence of gene
expression change was demonstrated using quantitative RT-PCR and ELISA analysis.
Results:  We show that Nurr1 regulates transcription of a small number of genes for pro-
inflammatory modulators of which the most significant is interleukin-8 (IL-8). We also demonstrate
increased synthesis and secretion of IL-8 further supporting a role for Nurr1 in inflammatory
signalling pathways.
Conclusion: Using microarray analysis we show that elevated levels of Nurr1 leads to increased
gene expression of pro-inflammatory genes: IL-8, Amphiregulin and Kit ligand in a model cell line.
This data provides further evidence for an additional role for Nurr1 in inflammation and may play
a role in the pathogenesis of rheumatoid arthritis.
Background
Nuclear receptors can generally be described as ligand
activated transcription factors that form a large super-
family of proteins. In humans 48 such receptors have
been identified [1] and are involved with an extensive
number of cellular processes throughout development
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and adult physiology [2]. Nuclear receptors are activated
through binding by a diverse range of natural and synthet-
ically produced ligand molecules including hormones,
fatty acids and antibiotics. In addition to the receptors
known to bind ligand, a group of nuclear receptors exist
for which a ligand has not been identified; these are
termed the orphan nuclear receptors. Among this group of
orphans is Nurr1 (NR4A2), a member of the NR4 group
of orphan nuclear receptors together with Nur77
(NR4A1) and NOR-1 (NR4A3) [3]. This family can bind
as monomers to DNA response elements in the promoters
of genes and activate transcription in the absence of ligand
[4]. Interestingly, this family of receptors are also capable
of binding as a heterodimer with the 9-cis-retinoic acid
receptor, RXR [5] or as a heterodimer with other Nur-fam-
ily members [6]. RXR as a heterodimer with Nurr1
remains active, suggesting that regulation can be modified
by the use of specific rexinoids to enhance the response of
these receptors to growth factors and therefore this could
provide a novel therapeutic avenue for treatment of Nurr1
regulated disease.
The structure of Nurr1 has recently be solved highlighting
differences between Nurr1 and the known liganded
nuclear receptors [7]. Based upon homology modelling,
the region in Nurr1 that would normally contain the lig-
and-binding pocket has been shown to be substantially
different from other nuclear receptors suggesting that
there is insufficient space in the putative ligand binding
pocket to accommodate a ligand. This may explain the
observations that Nurr1 is able to activate transcription in
a ligand independent manner and why no ligand has yet
been reported for Nurr1.
In contrast to the majority of nuclear receptors, Nurr1 is
encoded by an immediate early gene that is rapidly
induced in cells in response to external stimuli such as
cytokines. Nurr1 has been implicated in a number of
human diseases including Parkinson's disease [8,9], schiz-
ophrenia [10], alcohol dependence [11] and rheumatoid
arthritis [12]. In accordance with the nature of these dis-
eases, the expression of Nurr1 is observed in the develop-
ing and adult CNS and within the inflamed synovium of
the rheumatic joint [12-14].
A number of genes have been demonstrated to be regu-
lated by Nurr1; many of these are involved with the devel-
opment and maintenance of midbrain dopaminergic
neurons. These include tyrosine hydroxylase [4], Ret tyro-
sine kinase [15] and the dopamine transporter (SLC6A3)
[16]. The Nur-family members have also been shown to
play a pivotal role in regulating expression of CRH and
pro-opiomelanocortin (POMC) within the hypotha-
lamic-pituitary-adrenal (HPA) axis [6,17-19]. These stud-
ies, carried out in mouse pituitary cells, also demonstrate
that CRH is capable of causing increased expression of
Nurr1, suggesting the presence of a positive feedback
loop. More recently, studies in synovial tissue taken from
the rheumatoid joint have shown Nurr1 to be highly
expressed. In addition it has been demonstrated that
inflammatory cytokines are capable of increasing Nurr1
expression through NF-κB and CREB dependent signal-
ling and this elevation in Nurr1 leads to increased tran-
scription of CRH [12,20]. Whilst in the HPA axis, these
close Nur-family members are capable of sharing overlap-
ping roles, in primary synoviocytes, treatment with vari-
ous cytokines shows predominantly Nurr1 upregulation
[20]. Therefore in rheumatic synovium it is proposed that
Nurr1 is acting to exacerbate the inflammatory response
by driving a Nurr1-CRH positive feedback loop, indicat-
ing its potential as a target for possible therapeutic inter-
vention.
The purpose of this study was to further investigate the
role of Nurr1 in regulating inflammatory processes in syn-
ovial cells, and by using transcript profiling to identify
Nurr1 regulated genes in synoviocytes, which may be
playing a role in the pathology of rheumatoid arthritis.
Methods
Plasmid expression constructs
A reporter gene construct was generated by ligating oligo-
nucleotides representing 3 tandem repeated consensus
Nurr1 binding sites (NurRE), into the SpeI/AflII site of the
SW-gal construct as previously described [21], to generate
the construct: pNurRE3gal. The sense strand oligonucle-
otides (5'-3') for the insert were as follows, 3XNurRE:
ctagtgtgacctttattctcaaaggtcagtgacctttattctcaaaggtcagtgacctt-
tattctcaaaggtcac. Construction of the control plasmid
pCMV/hGH has been previously described [22]. Domi-
nant negative constructs were produced by fusing the
DNA binding domain of Nurr1 (aa94–365) and the Dro-
sophila engrailed domain (aa2–298) into the pcDNA3.1
expression vector to give pcDNA3.1-Nurr1-DN. The
Nurr1 wild type gene was PCR amplified from whole
brain RNA and cloned into the pcDNA3.1-V5-HIS vector
and the DNA sequence verified.
Cell culture
K4IM cells (a generous gift from E. Murphy) were cultured
in RPMI-1640 media supplemented with 10% (v/v) foetal
calf serum (FCS), 2 mM glutamine and 50 µg/ml penicil-
lin-streptomycin (Gibco BRL). HeLa cells were cultured in
DMEM media supplemented with 10% (v/v) foetal calf
serum (FCS), 2 mM glutamine and 50 µg/ml penicillin-
streptomycin (Gibco BRL). For reporter gene assays, HeLa
cells were cultured in phenol red-free DMEM supple-
mented with 0.5% (v/v) FCS, 2 mM glutamine and 50 µg/
ml penicillin-streptomycin.Journal of Inflammation 2005, 2:15 http://www.journal-inflammation.com/content/2/1/15
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Reporter gene assays
24 hrs prior to transfection, 2.2 × 106 HeLa cells were
seeded in a 9 cm2 dish, in full growth medium. Cells were
transfected by calcium phosphate precipitation with a
total of 20–25 µg DNA per 1 ml of precipitate as previ-
ously described [23]. Generally, 10–15 µg of reporter con-
struct was co-transfected with 2–5 µg of Nurr1 or empty
vector DNA (pcDNA3.1) and including 0.5 µg CMV/hGH
plasmid for data normalisation. 6 hrs post-transfection
the cells were exposed to osmotic shock (15% glycerol in
DMEM for 90 seconds) and the media replaced with phe-
nol-red free DMEM supplemented with 0.5% FCS (assay
medium). Cells were harvested 16–20 hrs later by incu-
bating the cells with trypsin-EDTA (phenol red free) for 3
min at 37°C. Cells were counted, seeded into 96 well
microtitre plates at 105  cells/well in 100 µl of assay
medium and incubated for a further 16–20 hrs. β-galac-
tosidase activity was measured using the spectrophoto-
metric substrate, CPRG (Boehringer) as previously
described [21]. Briefly, 100 µl of a cocktail containing 7 µl
50 mM CPRG, 7 µl Z buffer pH7 (600 mM Na2HPO4; 400
mM NaH2PO4; 100 mM KCl; 10 mM MgSO4; 500 mM β-
mercaptoethanol), 1 µl 20% SDS and 85 µl dH2O water
was added directly to each well and the plates incubated
at 37°C before an OD 570 nm measurement was taken.
Incubation times varied depending on the individual
assays but were typically 30 min–3 hrs. Secreted growth
hormone from the cell supernatants was measured using
a 2-antibody sandwich ELISA as previously described
[22].  β-galactosidase values were normalised using the
hGH values.
Determination of IL-8 protein levels
IL-8 was quantified using ELISA (R&D systems – D8050).
K4IM cells were resuspended in Amaxa solution "R" to a
concentration of 0.4 × 106 cells per 100 µl. A total of 2 µg
of DNA was transfected using the Amaxa Nucleofector fol-
lowing the manufacturer's protocol (A-23). Media was
collected 48 hr post nucleofection and used undiluted in
duplicate according to the manufacturer's instructions.
Quantitative RT-PCR
TaqMan real-time quantitative polymerase chain reaction
(PCR) assay was performed using an ABI Prism 7700
Sequence Detection System, according to the manufac-
turer's protocol (Applied Biosystems), sequences for
primers and probes can be found in Table 1. Additionally,
primers and probes for IL-8 were obtained as a pre-formu-
lated 20× mix from Applied Biosystems. Amplification of
GAPDH (primer/probe mix 4310884E) was performed to
standardize the quantification of target RNA, allowing rel-
ative quantitation using the ABI Prism 7700 SDS v1.9 soft-
ware. Briefly, 25 ng of a mixture of brain, placenta and
testis total RNA (Ambion 7962, 7950 & 7972) and subse-
quent 5-fold serial dilutions down to 1/3125 of neat were
amplified in triplicate for both GAPDH and each target
gene to produce a standard curve. RNA was extracted from
cells using TRIzol reagent (Gibco-BRL) according to the
manufacturer's guidelines. Total RNA was analysed and
quantified using the Agilent Bioanalyser 2100 with the
RNA Nano6000 chip. For the purpose of Taqman and RT-
PCR analysis, the RNA was DNase treated using the
DNase-Away kit (Ambion) according to manufacturer's
protocol. 5 µl of RNA at a concentration of 5 ng/µl was
dispensed in triplicate into optical 96-well plates for Taq-
man RT-PCR. Each sample was supplemented with both
respective forward, reverse primer and fluorescent
labelled probe in a total reaction volume of 25 µl using
Taqman Quantitect Probe Master-Mix and RT enzyme mix
(Qiagen – 204443). Each target probe was amplified in a
separate 96-well plate. All samples were incubated for an
initial reverse transcription reaction at 50°C for 30 min-
utes and then at 95°C for 15 minutes, followed by 40
cycles at 95°C for 15 seconds and 60°C for 1 minute.
DNA microarray
Nucleofection was used to transfect the following three
expression constructs into the K41M cell line: 1.
pcDNA3.1 blank vector (control); 2. pcDNA3.1-Nurr1-
WT (Nurr1 WT); 3. pcDNA3.1-Nurr1194–365EnR2–298 dom-
inant negative (DN) co-transfected with pcDNA3.1-
Table 1: Sequences for Taqman RT-PCR. Sequences for primers and probes were designed using Primer Express (Applied 
Biosystems).
Gene Size of product Primer Sequence (5'-3')
Nurr1 77 bp Forward TGTGTTCAGGCGCAGTATGG
Reverse TCCCGAAGAGTGGTAACTGTAGC
Probe CCTCGCCTCAAGGAGCCAGCC
AREG 70 bp Forward ACTCGGCTCAGGCCATTATG
Reverse AAAATGGTTCACGCTTCCCA
Probe TGCTGGATTGGACCTCAATGACACCTACT
KITLG 75 bp Forward TGGTGGCAAATCTTCCAAAAG
Reverse CAATGACTTGGCAAAACATCCA
Probe CATGATAACCCTCAAATATGTCCCCGGGJournal of Inflammation 2005, 2:15 http://www.journal-inflammation.com/content/2/1/15
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Nurr1-WT (Nurr1 DN/Nurr1 WT). Each transfection was
carried out in triplicate, thus generating 9 samples from
which RNA was extracted. Total RNA was extracted from
each sample using RNeasy kit (Qiagen – 74104). RNA
integrity and yield were analysed and quantified using the
Agilent Bioanalyser 2100 with the RNA Nano6000 chip
prior to synthesis of cRNA probes. Preparation of cRNA,
hybridization and scanning of the HG-U133 GeneChip
oligonucleotide arrays were performed according to the
manufacturer's protocol (Affymetrix, Santa Clara, CA).
GeneChip images were quantified and gene expression
values were calculated by Affymetrix Microarray suite ver-
sion 5.0 (Mas 5.0, Affymetrix). For statistical analysis a
one-way analysis of variance (ANOVA) was used to com-
pare Nurr1 WT to control samples. Prior to the test,
probesets that were absent and/or had an expression sig-
nal less than 200 in all samples were removed. Probesets
that had P-values less than 0.01 were considered statisti-
cally significant. A similar one-way ANOVA analysis
across each probeset was used to compare Nurr1 DN to
control samples. Candidate genes were retained if they
showed greater than 1.5-fold upregulation, (p < 0.01)
between the control and Nurr1 WT samples and yet no
significant regulation (p < 0.01) between the control and
Nurr1 DN samples. These remaining genes were then
manually chosen for genes exhibiting an ideal profile
(being changed with Nurr1 and returned towards basal
activity with Nurr D/N).
Results
Dominant negative Nurr1 blocks Nurr1 induced reporter 
gene expression
To demonstrate the transcriptional activity of Nurr1 and
its subsequent attenuation with dominant negative con-
structs, we used a reporter gene assay to show induction of
the LacZ gene under the control of NurRE's. In HeLa cells
transfected with the wildtype Nurr1 expression vector,
activation of NurRE driven reporter gene constructs was
observed. This is consistent with previous reports showing
that in the absence of a ligand this family of receptors are
constitutively active when assayed using transfected cell-
lines [24,25]. In order to assess the specific role of Nurr1
on gene expression in K4IM cells we used a dominant neg-
ative Nurr1, which contained the DNA binding domain of
the Nurr1 (2–298) fused to the Drosophila engrailed
repressor domain. This type of dominant negative has
been used extensively to study the role of transcription
factor knockout phenotypes [26,27]. Transfection of
K4IM cells with wildtype Nurr1 expression constructs
causes induction of expression of the reporter gene whilst
co-transfection of the dominant negative with the wild-
type Nurr1 attenuates this effect at a range of concentra-
tions (Figure 1). This dominant negative Nurr1 activity
was therefore used to assess the specific role of Nurr1
activity in K4IM cells.
Analysis of Nurr1 mediated gene expression in K4IM cells
The synovial fibroblast cell line K4IM was chosen as a
model cell line to explore the role of Nurr1 in pro-inflam-
matory signalling pathways relevant to the arthritic joint
[12,28]. Cells were transfected with Nurr1 constructs and
RNA extracted from cells 16 hours post nucleofection.
This was used to prepare cRNA probes for hybridisation to
HG-U133 gene chip arrays. Quality control assessment of
the Genechip arrays identified that scaling factors were
less than 3 fold apart, ratios of 5' versus 3' probe sets for
GAPDH and β-actin were close to 1 and background and
noise levels were acceptable. Genes were considered to be
Nurr1 dependent only if they exhibited a greater than 2
fold change (Nurr1-WT transfected cells compared to vec-
tor control) and only if their expression was attenuated by
co-transfection with the Nurr1 DN expression construct
(see Table 2). Only three genes were identified with this
profile Interleukin-8 (IL-8), Amphiregulin (AREG) and
Kit ligand (KITLG). The greatest change was seen with IL-
8, which was induced 5-fold (p = 10-4).
Nurr1 dependent regulation of pro-inflammatory genes
In order to confirm the observations from the microarray
analysis, K4IM cells were transfected with a Nurr1 expres-
sion construct and RNA harvested from cells after 16
hours. Quantitative RT-PCR analysis was then carried out
with expression changes normalised to GAPDH. K4IM
cells overexpressing Nurr1 showed increase expression of
Coexpression of a dominant negative-Nurr1 receptor atten- uates the transactivation activity of Nurr1-wild type in a β- Gal reporter assay Figure 1
Coexpression of a dominant negative-Nurr1 recep-
tor attenuates the transactivation activity of Nurr1-
wild type in a β-Gal reporter assay. HeLa cells coex-
pressing pCDNA3.1-Nurr1-WT and pcDNA3.1-Nurr1-DN 
in varying ratios demonstrates strong antagonist effects of 
dominant negative Nurr1 construct on Nurr1 transcriptional 
activity (pNurRE3gal), values normalised to cotransfected 
hGH, using an hGH sandwich ELISA assay. Values expressed 
represent the mean fold change ± SEM, compared to the 
reporter alone.Journal of Inflammation 2005, 2:15 http://www.journal-inflammation.com/content/2/1/15
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IL-8, KITLG and AREG transcripts compared to blank vec-
tor transfected cells confirming the observations from the
microarray experiments (Figure 2). In addition consistent
with the microarray data, the induced levels for each gene
were returned to basal levels by co-transfection with the
dominant negative Nurr1 construct (pcDNA3.1-Nurr1-
DN) (Figure 2).
Nurr1 dependent induction of IL-8 production in K4IM 
cells
To further confirm the functional consequences of ele-
vated levels of Nurr1 we determined effects on IL-8 pro-
tein production using a sandwich ELISA on the media
taken from Nurr1 transfected K4IM cells. The experiments
were carried out using increasing concentrations of Nurr1
plasmid DNA (pcDNA3.1-Nurr1-WT) and a dose depend-
ent increase in the amount of secreted IL-8 was observed
(Figure 3). These results indicate that in K4IM cells ele-
vated levels of Nurr1 leads directly to increased synthesis/
secretion of the pro-inflammatory cytokine IL-8.
Discussion
This study was designed to explore the potential link
between Nurr1, pro-inflammatory signalling and the
pathogenesis of rheumatoid arthritis using a synovial
fibroblast derived cell line, K4IM as a model system. Tran-
script profiling via Affymetrix microarrays was used to
examine the consequences of elevated Nurr1 levels in
K4IM cells. Overexpression of Nurr1 in K4IM cells
resulted in constitutive activity of the receptor as shown
by the reporter assay and this activity could be suppressed
by cotransfection with a dominant negative Nurr1 con-
struct (Figure 1). Given that Nurr1 is an immediate early
gene [19] and that transactivation activity using the
reporter system is observed within hours of transfection
(data not shown), we harvested RNA 16 hours following
transfection to maximise the chance of identifying Nurr1
primary targets as opposed to downstream secondary
effects. To have confidence in the Nurr1 dependent tran-
scription of elevated genes we compared expression pro-
files between cells transfected with Nurr1 alone or with a
mix of Nurr1 and dominant negative Nurr1. Using our
stringent cutoffs, only three genes: IL-8, Amphiregulin
and Kit ligand were upregulated more than 2-fold and
subsequently returned to basal levels by the presence of
the Nurr1 dominant negative, confirming the Nurr1
dependence. A list of probesets of 1.5-fold increase
between Nurr1-WT and blank vector control transfections
is provided as a supplementary table to show genes that
may be either increasing or decreasing in their expression
following Nurr1 transfection (see Additional file 1). This
small number of differentially expressed genes may be
representative of both the short time period of expression
and the specificity of Nurr1 signalling. Importantly all
three have recognized roles in inflammation. We exam-
ined in further detail the Nurr1-dependent induction of
these genes in K4IM cells and confirmed the microarray
observations using Taqman quantitative RT-PCR. Of these
three genes, the most highly induced gene was the inflam-
matory cytokine, IL-8 and for this reason we further dem-
onstrated using an IL-8 ELISA that Nurr1 specifically
induces release of IL-8 protein into the culture media from
K4IM cells (Figure 3). IL-8 has an established role in neu-
trophil recruitment via the CXCR1/2 receptors [29]
Amphiregulin and Kit ligand also have demonstrated
roles in inflammation [30,31]. Transgenic mice expressing
Amphiregulin under the control of keratin 14 promoter
display early-onset synovial inflammation and severe skin
pathology demonstrating a potential role for Amphiregu-
lin in psoriasis and psoriatic arthritis [30]. Kit ligand, also
known as Stem Cell Factor (SCF), has been shown to play
a role in activation of mast cells. Administration of SCF
into the airways of normal mice results in a dose depend-
ent increase in airway hyperreactivity via mast cell activa-
tion demonstrating the role of SCF in the development of
allergic airway inflammation and hyperreactivity [31]. In
addition, activation of the Kit receptor by SCF leads to the
phosphorylation of Akt which is necessary for IL-1-
dependent NF-κB transactivation [32], Akt has been pos-
Table 2: Differentially expressed genes following Nurr1 overexpression. K4IM cells were transfected in triplicate using the Amaxa 
Nucleofector system for each of the 3 conditions: 1. 5 µg pcDNA3.1 blank vector (control); 2. 2.5 µg pcDNA3.1-Nurr1-WT (Nurr1 
WT) and 2.5 µg pCDNA3.1 blank vector; 3. 2.5 µg pcDNA3.1-Nurr1-DN dominant negative (DN) co-transfected with 2.5 µg 
pCDNA3.1-Nurr1-WT (Nurr1 DN/Nurr1 WT). Cells were cultured for 16 hours prior to RNA extraction. Genes were identified from 
the Affymetrix U133A chip showing significant change between blank vector transfected synoviocytes and Nurr1 transfected K4IM 
cells (>2 fold) and for genes not significantly changed between blank vector and Nurr1 D/N transfected cells (with a p-value of < 0.01). 
In each case genes were manually selected that showed subsequent return to basal levels with dominant negative cotransfection.
Official HUGO Symbol Description RefSeqN Id Fold change p-value
IL8 Interleukin 8 NM_000584 5.04 0.00047
AREG Amphiregulin (schwannoma-derived growth factor) NM_001657 2.80 0.00037
KITLG KIT ligand NM_000899 2.23 0.00390Journal of Inflammation 2005, 2:15 http://www.journal-inflammation.com/content/2/1/15
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tulated to play a role in RA via its ability to regulate NF-κB
and also promote resistance to apoptosis through a
number of mechanisms [reviewed in [33]]. This role in
cell cycle control remains consistent with other NR4
group members, in particular the Nur77 having an estab-
lished role in TCR-mediated apoptosis of T hybridoma
cells [34,35].
Nurr1 has previously been shown to act as a point of con-
vergence for multiple inflammatory signals via CREB-1
and NFκB signalling [20]. Subsequent studies have shown
Nurr1 and other NR4 family members to be involved in
the inflammatory cascade of several stimuli, including
TNFα-induced PAI-1 expression [36] and in LPS/TNFα
stimulated macrophages [37]. TNFα plays a critical role in
the stimulation of leukocyte recruitment and cytokine
production and antibodies which act by blocking TNFα
signalling have been shown to have clinically beneficial
effects in RA patients [38]. Therefore we speculate that in
addition to established NFκB signalling activating IL-8
expression [39], TNFα and other inflammation stimula-
tors can act by regulating Nurr1 expression that in turn
can regulate IL-8 expression either directly or indirectly.
Ongoing work within our laboratory aims to address the
exact mechanisms for Nurr1 activity on IL-8, Amphiregu-
lin and Kit ligand gene expression.
In summary we have demonstrated using microarray anal-
ysis that elevated levels of Nurr1 leads to increased gene
expression of IL-8, Amphiregulin and Kit ligand in the
model cell line, K4IM. Moreover we have confirmed these
Nurr1 dependent transcriptional changes using Taqman
RT-PCR and demonstrated an increase in synthesis/secre-
tion of IL-8 in cells transfected with Nurr1. We speculate
that the elevated levels of Nurr1 observed in rheumatoid
arthritis can potentially exacerbate the disease process in
RA. Therefore, blocking the activation of Nurr1, or modi-
fying the transactivation potential of Nurr1 through the
use of rexinoids, methotrexate [40] or thiopurine ana-
logues [41] represent a potential therapeutic option for
rheumatoid arthritis and other inflammatory or allergic
diseases.
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Effect of dominant negative Nurr1 on Nurr1 induced inflam- matory gene expression Figure 2
Effect of dominant negative Nurr1 on Nurr1 induced 
inflammatory gene expression. Demonstration that 
Nurr1 causes increased expression of IL-8, AREG and KITLG 
mRNA that can be attenuated with the coexpression of 
Nurr1-D/N in K4IM cells using Taqman Quantitative RT-
PCR. Values expressed represent the mean fold change ± 
SEM, compared to the blank vector control and is derived 
from three experiments normalised in each case to GAPDH 
gene expression at 24 hr post transfection. Similar results 
were observed in a further two independent experiments.
Effects on increased expression of Nurr1 on IL-8 release Figure 3
Effects on increased expression of Nurr1 on IL-8 
release. 4 × 105 K4IM cells were transfected using the 
Amaxa Nucleofector with increasing amount of pCDNA3.1-
Nurr1-WT, total amount of transfected DNA was 2 µg. Cell 
media was removed after 48 hour incubation and analysed 
for the amount of IL-8 present in the culture media using 
ELISA (R&D systems). Increased production of IL-8 protein 
secreted into the cell media was observed in a dose depend-
ent manner with Nurr1 expression plasmid. Values 
expressed represent the mean concentration of IL-8 ± SEM.Journal of Inflammation 2005, 2:15 http://www.journal-inflammation.com/content/2/1/15
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